For clinicians and patients navigating CoQ10 supplementation decisions, recent evidence clarifies which factors actually influence therapeutic outcomes. While marketing emphasizes molecular form, research reveals that manufacturing process and formulation technology matter significantly more.
Three essential findings should guide supplement selection: First, your body converts between ubiquinone and ubiquinol with 95-98% circulating as ubiquinol regardless of initial form—meaning metabolic conversion isn’t a limiting factor. Second, crystal-dispersed ubiquinone formulations demonstrate double the bioavailability of ubiquinol soft gels, suggesting that manufacturing innovation outweighs molecular form in determining absorption. Third, clinical trials show equivalent cardiovascular and metabolic outcomes for both molecular forms when appropriately formulated.
These findings suggest healthcare providers should counsel patients to prioritize product quality, bioavailability data, and manufacturing processes rather than marketing claims emphasizing one molecular form. Cost-effectiveness and formulation quality should guide evidence-based supplement recommendations.
Read the full article on GMJ Newsroom.
Was this article helpful?
